The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: Results of a phase 1 study

Clinical Cancer Research

Volumn 12, Issue 9, 2006, Pages 2834-2840

  Hande, Kenneth R ^a,c   Hagey, Anne ^b   Berlin, Jordan ^a   Cai, Yingna ^b   Meek, Kysa ^b   Kobayashi, Hiro ^a   Lockhart, A Craig ^a   Medina, Diane ^b   Sosman, Jeffrey ^a   Gordon, Gary B ^b   Rothenberg, Mace L ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b ABBOTT LABORATORIES   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMITOTIC AGENT; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; CELL CYCLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG STRUCTURE; DRUG TOLERABILITY; FATIGUE; FECES IMPACTION; FEMALE; GLUCURONIDATION; HUMAN; ILEUS; MALE; MITOSIS; MYALGIA; NAUSEA; NEUROPATHY; PARESTHESIA; PRIORITY JOURNAL; SOLID TUMOR; SULFATION;

ADMINISTRATION, ORAL; ADULT; AGED; BIOLOGICAL AVAILABILITY; CELL DIVISION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; SAFETY; SULFONAMIDES;

EID: 33646741205     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2159     Document Type: Article

References (17)

1. Gelfand V, Bershadsky A. Microtubulin dynamics: mechanism, regulation and function. Annu Rev Cell Biol 1991;7:93-116.
2. Rowinsky E, Donehower R. Antimicrotubule agents. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology, 5th ed. Philadelphia: Lippincott-Raven; 1997. p. 468-83.
3. Jordan MA, Toso RJ, Thrower D, et al. Mechanism of mitotic block and inhibition of cell proliferation by Taxol at low concentrations. Proc Natl Acad Sci U S A 1993;90:9552-6.
4. Raynaud FI, Judson IR. Synthetic microtubule inhibitors. Drugs Future 1996;21:65-70.
5. Wilson L, Jordan MA. Pharmacological profiles of microtubulin function. In: Hyams JF, Lloyd CD, editors. Microtubules. New York: Wiley-Liss; 1993. p. 59.
6. Ogawa M, Ariyoshi Y. New anticancer drugs under clinical trials in Japan. Hematol Oncol Clin North Am 1994;8:277-87.
7. Koyanagi N, Nagasu T, Fujita F, et al. In vivo tumor growth inhibition produced by a novel sulfonamide, E7010. Cancer Res 1994;54:1702-6.
8. Kikuchi A. Antitumor effects of a novel sulfonamide E7010 on human ovarian cancer cell lines in vitro and in vivo. Acta Med Biol 1996;44:193-7.
9. Yoshino H, Ueda N, Niijima J, et al. Novel sulfonamides as potential systemically active antitumor agents. J Med Chem 1992;35:2496-7.
10. Ozawa Y, Wantanabe T, Koyanagi N, et al. E7070, a novel sulfonamide agent with potent antitumor activity in vitro and in vivo. Eur J Cancer 2001;37:2275-82.
11. Yoshimatsu K, Yamaguchi A, Yoshino H, Koyanangi N, Kitoh K. Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin. Cancer Res 1997;57:3208-13.
12. Yamamoto K, Noda K, Yoshimura A, Fukuoka M, Furuse K, Niitani H. Phase I study of E7010. Cancer Chemother Pharmacol 1998;42:127-34.
13. CTEP, NCI: Common toxicity criteria manual, version 2.0. Bethesda (MD); National Cancer Institute; 1999. p. 1-35.
14. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
15. Putterman C, Ben-Chetrit E, Caraco Y, Levy M. Colchicine intoxication: clinical pharmacology, risk factors, features and management. Semin Arthritis Rheum 1991;21:143-55.
16. Folpini A, Furfori P. Colchicine toxicity: clinical features and treatment. Massive overdose case report. J Toxicol Clin Toxicol 1995;33:71-7.
17. Sprague E, Fleming GF, Carr R, et al. Phase I study of 21-day continuous dosing of the oral anti-mitotic agent ABT-751 [abstract]. Proc Am Soc Clin Oncol 2003;22:129.